OSE Immunotherapeutics Launches Global Phase 3 Trial for Cancer Vaccine
OSE Immunotherapeutics, a French biotech firm, launched a global Phase 3 trial for its cancer vaccine Tedopi, securing \$9.3 million in public funding and partnerships with AbbVie and Boehringer Ingelheim, resulting in a 66% stock increase over the past year.
OSE Immunotherapeutics Launches Global Phase 3 Trial for Cancer Vaccine
OSE Immunotherapeutics, a French biotech firm, launched a global Phase 3 trial for its cancer vaccine Tedopi, securing \$9.3 million in public funding and partnerships with AbbVie and Boehringer Ingelheim, resulting in a 66% stock increase over the past year.
Progress
48% Bias Score
CD74 Protein Identified as Potential Biomarker for Colorectal Cancer Immunotherapy Response
Researchers have identified the protein CD74 as a potential biomarker to predict immunotherapy response in colorectal cancer patients, improving treatment selection and potentially expanding access to immunotherapy.
CD74 Protein Identified as Potential Biomarker for Colorectal Cancer Immunotherapy Response
Researchers have identified the protein CD74 as a potential biomarker to predict immunotherapy response in colorectal cancer patients, improving treatment selection and potentially expanding access to immunotherapy.
Progress
44% Bias Score
Shared Neoantigens in Endometrial Cancers Suggest Potential for Nous-209 Vaccine
An Italian study found that endometrial cancers with mismatch repair deficiency share many neoantigens with colon and stomach cancers, suggesting the potential use of the existing Nous-209 therapeutic vaccine; 80% of 35 patients showed at least one neoantigen present in Nous-209.
Shared Neoantigens in Endometrial Cancers Suggest Potential for Nous-209 Vaccine
An Italian study found that endometrial cancers with mismatch repair deficiency share many neoantigens with colon and stomach cancers, suggesting the potential use of the existing Nous-209 therapeutic vaccine; 80% of 35 patients showed at least one neoantigen present in Nous-209.
Progress
20% Bias Score
Johnson & Johnson Targets Autoimmune Diseases with Novel Therapies
Johnson & Johnson, a leader in immunology, is researching treatments for over 80 autoimmune and alloantibody diseases affecting nearly 240 million globally, focusing on three segments with a targeted approach to lower pathogenic IgG antibodies while preserving overall immune function, addressing a c...
Johnson & Johnson Targets Autoimmune Diseases with Novel Therapies
Johnson & Johnson, a leader in immunology, is researching treatments for over 80 autoimmune and alloantibody diseases affecting nearly 240 million globally, focusing on three segments with a targeted approach to lower pathogenic IgG antibodies while preserving overall immune function, addressing a c...
Progress
36% Bias Score
Russia Begins Human Trials of Personalized Cancer Vaccine
Russia is conducting human clinical trials for "EnteroMix," a personalized cancer vaccine using oncolytic viruses, targeting patients with solid tumors who have exhausted standard treatment options, offering a potentially revolutionary approach to cancer treatment.
Russia Begins Human Trials of Personalized Cancer Vaccine
Russia is conducting human clinical trials for "EnteroMix," a personalized cancer vaccine using oncolytic viruses, targeting patients with solid tumors who have exhausted standard treatment options, offering a potentially revolutionary approach to cancer treatment.
Progress
44% Bias Score
World-First Personalized mRNA Cancer Vaccine Shows Promise in Treating Urinary Tract Cancer
A 75-year-old woman at Bari's Policlinico hospital became the first globally to receive a personalized mRNA cancer vaccine (cevumeran) alongside nivolumab immunotherapy after surgery for high-risk urinary tract cancer; this innovative treatment is designed to address specific tumor mutations, offeri...
World-First Personalized mRNA Cancer Vaccine Shows Promise in Treating Urinary Tract Cancer
A 75-year-old woman at Bari's Policlinico hospital became the first globally to receive a personalized mRNA cancer vaccine (cevumeran) alongside nivolumab immunotherapy after surgery for high-risk urinary tract cancer; this innovative treatment is designed to address specific tumor mutations, offeri...
Progress
56% Bias Score
Modified Bird Virus Shows Promise in Treating Multiple Cancers
A Chinese study showed a modified bird virus, NDV-GT, shrunk or stopped tumor growth in 22 of 23 patients with eight different advanced cancers in a trial; further trials are planned.
Modified Bird Virus Shows Promise in Treating Multiple Cancers
A Chinese study showed a modified bird virus, NDV-GT, shrunk or stopped tumor growth in 22 of 23 patients with eight different advanced cancers in a trial; further trials are planned.
Progress
40% Bias Score
CAR T-cell Therapy for Breast Cancer: Early Trials Show Promise, but Challenges Remain
Currently, 16 active phase I/II clinical trials are investigating CAR T-cell therapy for various solid tumors, including breast cancer, primarily in the US, focusing on safety and feasibility; results are preliminary, showing some encouraging but limited data, with no phase III trials yet.
CAR T-cell Therapy for Breast Cancer: Early Trials Show Promise, but Challenges Remain
Currently, 16 active phase I/II clinical trials are investigating CAR T-cell therapy for various solid tumors, including breast cancer, primarily in the US, focusing on safety and feasibility; results are preliminary, showing some encouraging but limited data, with no phase III trials yet.
Progress
40% Bias Score
CAR T-Cell Therapy Shows Promise for Autoimmune Disease Cure
UK scientists are trialing CAR T-cell therapy—a cancer treatment—to cure autoimmune disorders like lupus, with early results showing potential for remission and prevention, although long-term effects are still unknown.
CAR T-Cell Therapy Shows Promise for Autoimmune Disease Cure
UK scientists are trialing CAR T-cell therapy—a cancer treatment—to cure autoimmune disorders like lupus, with early results showing potential for remission and prevention, although long-term effects are still unknown.
Progress
56% Bias Score
Russia Announces Free Personalized Cancer Vaccine for 2025 Rollout
Russia's health ministry announced a free, personalized cancer vaccine for patients, launching in early 2025, addressing the nation's rising cancer rates exceeding 635,000 cases in 2022, using RNA technology similar to Western approaches.
Russia Announces Free Personalized Cancer Vaccine for 2025 Rollout
Russia's health ministry announced a free, personalized cancer vaccine for patients, launching in early 2025, addressing the nation's rising cancer rates exceeding 635,000 cases in 2022, using RNA technology similar to Western approaches.
Progress
32% Bias Score
GLP-1 Weight Loss Drugs May Reduce Breast Cancer Treatment Efficacy
A study of hundreds of women with triple-negative breast cancer found that those taking GLP-1 weight-loss drugs like Ozempic and Wegovy had significantly lower remission rates (28% vs 63%) after treatment, suggesting interference with chemotherapy and immunotherapy effectiveness.
GLP-1 Weight Loss Drugs May Reduce Breast Cancer Treatment Efficacy
A study of hundreds of women with triple-negative breast cancer found that those taking GLP-1 weight-loss drugs like Ozempic and Wegovy had significantly lower remission rates (28% vs 63%) after treatment, suggesting interference with chemotherapy and immunotherapy effectiveness.
Progress
52% Bias Score
Oncolytic Virus Immunotherapy Shows Promise for Advanced Melanoma
In a phase 2 clinical trial, combining the oncolytic virus immunotherapy RP1 with nivolumab resulted in a 30% overall response rate and 15% complete response rate in 140 patients with advanced melanoma unresponsive to prior immunotherapy, leading to FDA Breakthrough Therapy designation.
Oncolytic Virus Immunotherapy Shows Promise for Advanced Melanoma
In a phase 2 clinical trial, combining the oncolytic virus immunotherapy RP1 with nivolumab resulted in a 30% overall response rate and 15% complete response rate in 140 patients with advanced melanoma unresponsive to prior immunotherapy, leading to FDA Breakthrough Therapy designation.
Progress
48% Bias Score